How accessible will MDMA and psilocybin be, following the Australian government's decision to make them available as Schedule 8 controlled drugs?

Probably not very accessible at all, for a bunch of reasons: First, the Therapeutic Goods Administration has determined that from July 1 2023, MDMA to treat PTSD and psilocybin to treat treatment-resistant depression may be approved for patient use by a qualified psychiatrist.

tga.gov.au/sites/default/…

1/ You can *not* get CBD over-the-counter at pharmacies in Australia

You won't be able to for at least 1-2 years and possibly never

There has been a lot of misleading news coverage about this which I think is irresponsible and could end up harming people 2/ The TGA has determined that low-dose CBD products, which have been proven through clinical trials to treat specific symptoms at low doses, might be available over-the-counter, once they have gone through an expensive and time consuming drug approval process

1/ I want to draw your attention to a great #cannabis #business #intelligence report just released from @FreshleafA which is free to download. Disclosure: they’re a past client of mine, but I wouldn’t promote this report if it wasn’t awesome freshleafanalytics.com.au 2/ The best part of this analysis is it’s based on proprietary data taken from the largest chain of cannabis clinics in #Australia. So, although the patient access data I publish is more comprehensive, theirs is more precise. Here are the highlights:

1/7 Everything you ever wanted to know about #patient #access to #medical #cannabis in #Australia in one article. Stoked to have co-written this with Dr Benson from @Lambert_Usyd! And please enjoy these bonus graphs updated with new data :D healtheuropa.eu/health-europa-… @HealthEuropa 2/7 First off, some of you may have already seen me post this a couple of weeks ago, but here are the national figures for SAS-B approvals up to June 2019